Analyzing Minerva Surgical (NASDAQ:UTRS) & Penumbra (NYSE:PEN)

Penumbra (NYSE:PENGet Rating) and Minerva Surgical (NASDAQ:UTRSGet Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Institutional & Insider Ownership

80.5% of Penumbra shares are held by institutional investors. Comparatively, 69.6% of Minerva Surgical shares are held by institutional investors. 5.5% of Penumbra shares are held by company insiders. Comparatively, 7.0% of Minerva Surgical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Penumbra and Minerva Surgical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Penumbra 0 1 8 0 2.89
Minerva Surgical 1 0 3 0 2.50

Penumbra currently has a consensus target price of $218.78, indicating a potential upside of 25.24%. Minerva Surgical has a consensus target price of $11.50, indicating a potential upside of 480.81%. Given Minerva Surgical’s higher possible upside, analysts plainly believe Minerva Surgical is more favorable than Penumbra.


This table compares Penumbra and Minerva Surgical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Penumbra -2.40% 0.97% 0.71%
Minerva Surgical -17.89% N/A -9.17%

Valuation and Earnings

This table compares Penumbra and Minerva Surgical’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Penumbra $747.59 million 8.85 $5.28 million ($0.52) -335.94
Minerva Surgical $52.10 million 1.10 -$21.46 million N/A N/A

Penumbra has higher revenue and earnings than Minerva Surgical.


Penumbra beats Minerva Surgical on 9 of the 11 factors compared between the two stocks.

About Penumbra

(Get Rating)

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

About Minerva Surgical

(Get Rating)

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with's FREE daily email newsletter.